Wolff-Parkinson-White Syndrome: Diagnosis, Risk Stratification, and Catheter Ablation

Wolff-Parkinson-White Syndrome: Diagnosis, Risk Stratification, and Catheter Ablation

By gomdori, MD · Cardiology · Evidence-based clinical guideline

Executive Summary

Wolff-Parkinson-White (WPW) syndrome is the clinical syndrome of ventricular pre-excitation on the resting 12-lead ECG (short PR <120 ms, delta wave, QRS ≥110-120 ms with secondary ST-T abnormalities) combined with documented arrhythmia symptoms. The substrate is an accessory pathway (AP) - an embryologic remnant of fetal AV connections - that bypasses the AV node and directly connects atrial to ventricular myocardium, allowing rapid conduction without the AV nodal decremental gating that normally protects ventricles from atrial tachyarrhythmias. Pre-excitation prevalence on routine ECG is 0.15-0.25%, but the symptomatic WPW SYNDROME affects approximately one-third of those individuals. Three clinical scenarios drive management: (1) orthodromic atrioventricular reentrant tachycardia (AVRT) - 80-95% of WPW arrhythmias - a narrow QRS regular tachycardia at 150-250 bpm with antegrade conduction down the AV node and retrograde conduction up the AP; (2) antidromic AVRT - rare (5-10%) - a wide QRS regular tachycardia with antegrade conduction down the AP and retrograde via the AV node, mimicking ventricular tachycardia; and (3) pre-excited atrial fibrillation - the LIFE-THREATENING emergency in which AF impulses bypass the AV node and conduct rapidly through the AP, causing irregular wide-complex tachycardia at rates often exceeding 250-300 bpm with degeneration to ventricular fibrillation and sudden cardiac death.

Acute management depends on hemodynamic stability and rhythm: stable orthodromic AVRT responds to vagal maneuvers, adenosine 6 mg IV rapid push, then 12 mg if unsuccessful, or beta-blockers; stable antidromic AVRT or pre-excited AF requires procainamide 20-50 mg/min IV up to 17 mg/kg or ibutilide 1 mg IV over 10 min (NOT AV nodal blockers, which can paradoxically accelerate AP conduction); unstable patients require synchronized cardioversion at 100-200 J biphasic. Critical drug rule: AVOID adenosine, verapamil, diltiazem, beta-blockers, and digoxin in any wide-complex tachycardia where pre-excited AF is possible - these AV nodal blockers can degenerate the rhythm to ventricular fibrillation. Definitive therapy for symptomatic WPW is catheter ablation of the accessory pathway via radiofrequency energy with success rates exceeding 95% and complication rates <2% in experienced centers. Asymptomatic WPW patients require risk stratification with exercise testing and electrophysiology study; high-risk asymptomatic individuals (shortest pre-excited RR ≤250 ms during AF, multiple pathways, septal location) should be offered prophylactic ablation.

0.15-0.25%
Pre-excitation prevalence
>95%
Ablation success
≤250 ms
SPERRI = high risk
~0.1%/yr
Sudden death risk

S1. Pathophysiology and Accessory Pathway Anatomy

During normal cardiac development, the atria and ventricles are electrically connected only through the AV node and bundle of His. Fetal AV ring myocardium is normally absorbed during the first trimester. When this absorption fails, residual muscular bridges - accessory pathways - persist between atrial and ventricular myocardium across the AV groove. Unlike the AV node, accessory pathways exhibit "all-or-none" conduction without the decremental delay that normally limits ventricular response rate during atrial tachyarrhythmias. The pathway has fast conduction velocity (similar to ventricular myocardium) and short refractory periods, allowing 1:1 conduction at rates often exceeding 300 bpm.

Accessory pathway location is described by the AV groove position relative to standard cardiac orientation. Approximately 50-60% are left-sided free wall (commonly accessed via retrograde aortic or trans-septal approach for ablation), 25-30% are posteroseptal, 15-20% are right-sided free wall, and 5-10% are anteroseptal/midseptal (highest risk for AV block during ablation due to proximity to the compact AV node). Multiple pathways occur in 5-10% of patients, identified by changing delta wave morphology between sinus beats or during EP study mapping.

Pre-Excitation Electrophysiology

During sinus rhythm, the atrial impulse simultaneously enters both the AV node (slow, decremental conduction with AH delay 60-130 ms) and the accessory pathway (fast, non-decremental). Because AP conduction reaches the ventricle FIRST, a portion of ventricular myocardium begins to depolarize before the AV nodal-His-Purkinje wavefront arrives. This early depolarization creates the characteristic delta wave - a slurred upstroke at the start of the QRS - representing slow myocyte-to-myocyte spread from the pathway insertion site before the rapid Purkinje system takes over. As the His-Purkinje wavefront catches up and depolarizes the rest of the ventricle, the QRS continues normally, producing the fusion complex of pre-excitation (delta + normal QRS).

The DEGREE of pre-excitation depends on relative conduction times: rapid AP conduction with slow AV nodal conduction yields large delta waves; conversely, sympathetic stimulation that accelerates AV nodal conduction may MINIMIZE pre-excitation, producing intermittent or "concealed" patterns. "Concealed" accessory pathways (~30% of WPW patients in EP studies) conduct only RETROGRADE (V to A); they do not produce delta waves on resting ECG but still support orthodromic AVRT. "Manifest" pathways conduct antegrade (A to V) producing visible pre-excitation. Both types support orthodromic AVRT, but only manifest pathways produce pre-excited AF and sudden death risk.

S2. ECG Recognition and Pathway Localization

Resting ECG Findings

FeatureDescription
Short PR interval<120 ms (normal 120-200 ms); reflects fast AP conduction bypassing AV nodal delay
Delta waveSlurred initial upstroke of QRS (first 30-50 ms); polarity (positive/negative) helps localize the pathway
Wide QRS≥110-120 ms in adults due to early ventricular activation via AP plus normal His-Purkinje activation
Secondary ST-T abnormalitiesST depression and T wave inversion oppositely directed to delta/QRS; reflects abnormal repolarization, NOT ischemia
"WPW patterns" by lead V1Type A (positive delta + R wave V1, mimics RBBB) = LEFT-sided pathway; Type B (negative delta + QS in V1) = RIGHT-sided

Don't Mistake Pre-Excitation for Pathology

The ST-T changes of pre-excitation are commonly misdiagnosed as ischemia, infarction, or LV hypertrophy. Look for the SHORT PR and DELTA WAVE before interpreting Q waves, ST changes, or T inversions. If pre-excitation is intermittent (some beats normal, some pre-excited), suspect a pathway with marginal antegrade conduction (lower sudden death risk). Always compare with prior ECGs.

Three Arrhythmias of WPW

ArrhythmiaMechanismQRS MorphologyTreatment
Orthodromic AVRT (80-95%)Antegrade AV node → ventricle → retrograde AP → atriumNarrow QRS, regular, 150-250 bpm; retrograde P wave often visible after QRS in inferior leadsVagal maneuvers, adenosine, beta-blockers; AV nodal blockers SAFE here
Antidromic AVRT (5-10%)Antegrade AP → ventricle → retrograde AV node → atriumWIDE QRS (full pre-excitation), regular, 150-250 bpm; mimics VTProcainamide, ibutilide, cardioversion; AV nodal blockers UNSAFE
Pre-excited atrial fibrillationAF impulses cross AP without AV nodal protectionWIDE, IRREGULARLY IRREGULAR QRS, often >250 bpm; varying morphologiesProcainamide, ibutilide, IMMEDIATE cardioversion if unstable; AV nodal blockers CONTRAINDICATED

Pathway Localization Algorithms

Several validated 12-lead algorithms (Arruda, Milstein, Fitzpatrick) predict pathway location from delta wave polarity and QRS morphology, useful for pre-procedural planning before EP study. Key principles:

  • Lead V1 polarity: Positive delta + R wave dominant = LEFT-sided (Type A); negative delta + QS pattern = RIGHT-sided (Type B)
  • Inferior lead delta polarity: Negative delta in II, III, aVF suggests posteroseptal or right-posterior pathway; positive delta in inferior leads suggests anterior/anterolateral pathway
  • Lead I delta polarity: Negative delta in I = left lateral/free wall; positive delta in I = right-sided or septal
  • QRS axis and transition: Late precordial transition (V4-V5) suggests right-sided; early transition (V1-V2) suggests left-sided

Final localization is determined at electrophysiology study by 3D electroanatomic mapping; pre-procedural algorithms guide initial catheter approach (retrograde aortic vs trans-septal vs right atrial mapping).

S3. Acute Management by Rhythm

The single most important decision in acute WPW management is recognizing pre-excited atrial fibrillation, since standard SVT/AF treatments (adenosine, verapamil, diltiazem, beta-blockers, digoxin) can be FATAL. The mantra: an irregularly irregular WIDE complex tachycardia is pre-excited AF until proven otherwise.

Stable Orthodromic AVRT (Narrow QRS, Regular)

StepTherapyNotes
1Vagal maneuvers (Valsalva, modified Valsalva, carotid sinus massage)Modified Valsalva (REVERT trial) terminates 43% vs 17% standard; safe and free
2Adenosine 6 mg IV rapid push (cubital vein, large bore, saline flush) → 12 mg if unsuccessful → may repeat 12 mgTerminates >90% of orthodromic AVRT; warn patient about flushing/chest pressure/sense of impending doom; CAUTION if pre-excited AF cannot be excluded
3IV beta-blocker: metoprolol 5 mg IV over 2 min, may repeat × 2If adenosine fails or is contraindicated; avoid in any wide-complex tachycardia
4IV diltiazem 0.25 mg/kg IV (15-20 mg) over 2 minAlternative non-DHP CCB if beta-blocker contraindicated; SAFE in narrow-complex orthodromic AVRT
5Synchronized cardioversion 50-100 J biphasic if drug-refractory or hemodynamic instability developsAlways have pads on patient before adenosine in case of pre-excited AF degeneration

Pre-Excited Atrial Fibrillation (Wide QRS, Irregularly Irregular) - EMERGENCY

The AV Nodal Blocker Rule (CRITICAL)

In any WIDE-complex tachycardia where pre-excited AF cannot be excluded, AVOID:

  • Adenosine (can shorten AP refractory period)
  • Verapamil and diltiazem (block AV node, leaving ALL conduction via the AP)
  • Beta-blockers (same mechanism)
  • Digoxin (slows AV nodal conduction, accelerates AP)

Blocking the AV node in pre-excited AF eliminates the protective AV nodal filter, forcing 1:1 AP conduction at atrial rates of 300-600/min and risking degeneration to ventricular fibrillation. Multiple cardiac arrests have been reported with verapamil in undiagnosed WPW pre-excited AF.

StatusTherapy
UNSTABLE (hypotension, ischemia, altered mental status, pulmonary edema)Synchronized cardioversion 200 J biphasic immediately; sedation if time permits
STABLE pre-excited AFFirst-line: procainamide 20-50 mg/min IV, max 17 mg/kg or until rhythm converts, hypotension, QRS widens >50% baseline, or QT >500 ms; alternative: ibutilide 1 mg IV over 10 min, may repeat × 1 dose if needed (caution with QT and torsades); pre-treat hypomagnesemia
If drugs fail or instability developsSynchronized cardioversion 200 J biphasic

Antidromic AVRT (Wide QRS, REGULAR)

Treat as wide-complex tachycardia of unknown origin. Procainamide IV is preferred; ibutilide acceptable. Avoid AV nodal blockers since the antegrade limb is the AP. Synchronized cardioversion at 100-200 J for instability or drug failure.

When to Consult Electrophysiology

Refer urgently for: (1) any documented pre-excited AF episode (immediate ablation indication); (2) any sustained antidromic AVRT; (3) syncope or aborted sudden cardiac death; (4) recurrent symptomatic orthodromic AVRT despite medical therapy or patient preference; (5) high-risk occupations (pilots, professional drivers, athletes) regardless of symptoms; (6) all symptomatic WPW patients for shared decision-making about ablation; (7) asymptomatic WPW with high-risk features on exercise testing or non-invasive evaluation.

WPW Syndrome — Procedure Steps Surgical stepper: WPW Syndrome — Procedure Steps WPW Syndrome — Procedure Steps 1 AVRT acute Stable orthodromic: vagal maneuvers → adenosine 6mg → 12mg IV; unstable: synchronized cardioversion 2 Pre-excited AF acute AVOID adenosine, BB, CCB, digoxin (block AV node → preferentially conduct down accessory → can cause 3 Risk stratification Asymptomatic WPW: exercise stress test (loss of pre-excitation = good); EP study for high-risk profe 4 Catheter ablation (1st-line) For all symptomatic WPW; selected asymptomatic high-risk; success rate 95%; 1-day procedure 5 Medical (long-term) For patients declining ablation: flecainide 100mg BID OR propafenone 150mg TID (if no structural HD) 6 Special situations Pregnancy: ablation deferred if possible; pediatric: high-risk asymptomatic ablation often considere
WPW Syndrome — Procedure Steps

S4. Catheter Ablation and Long-Term Management

Radiofrequency catheter ablation is the definitive curative therapy for WPW syndrome. Performed under conscious sedation or general anesthesia in an electrophysiology lab, the procedure involves: (1) baseline EP study to confirm AP characteristics (location, antegrade/retrograde refractory periods, multiple pathways); (2) 3D electroanatomic mapping to localize the AP insertion site precisely; (3) RF energy delivery (40-50 W, 60 sec per lesion) to ablate the pathway; (4) post-ablation testing to confirm bidirectional block.

Outcome / ComplicationRate
Acute success (loss of pre-excitation and AVRT non-inducibility)95-98% for free wall pathways; 90-95% for septal pathways
Long-term recurrence3-8% within 1 year (re-ablation success >90%)
Vascular complication (femoral hematoma, AV fistula, retroperitoneal bleed)1-2%
Cardiac tamponade0.5-1%; emergency pericardiocentesis available in lab
AV block requiring permanent pacemaker0.5-1% overall; up to 3-5% for septal/parahisian pathways
Stroke (left-sided pathways with retrograde aortic approach)0.1-0.5%; periprocedural anticoagulation reduces
Procedural mortality0.05-0.1%

Post-Ablation Care

Most patients are discharged same day or next morning. Activity restriction for 5-7 days for vascular access site healing. ECG at 1 week and 1 month confirms loss of pre-excitation. Patients with no recurrence at 6-12 months can be considered cured. Athletes and high-risk occupations may be cleared for unrestricted activity after documented success. Anticoagulation is not routinely needed beyond the periprocedural period unless other indications exist.

Special Considerations

PopulationManagement Principle
Pediatric WPW (age <5 yr)Many will lose pre-excitation spontaneously by age 5; defer ablation unless life-threatening arrhythmia or persistent symptoms
PregnancyDefer elective ablation until postpartum; manage acute arrhythmias with adenosine (orthodromic) or DC cardioversion (pre-excited AF); procainamide acceptable
Ebstein anomalyStrong association with right-sided and multiple APs (~25%); refer to congenital EP specialist
HCM with WPWConsider familial PRKAG2 syndrome (glycogen storage disease mimicking WPW); genetic testing if young, family history
AthletesSymptomatic athletes need ablation before return to competitive sports; asymptomatic athletes need risk stratification per consensus guidelines

S5. Asymptomatic WPW: Risk Stratification

The annual sudden cardiac death risk in asymptomatic WPW is low (approximately 0.1%/year, lifetime risk 3-4%), but is non-zero and warrants risk assessment. Higher-risk features that warrant prophylactic ablation discussion:

Risk Stratification ModalityThresholdSignificance
Loss of pre-excitation during exerciseSudden, abrupt loss at moderate workloadLOW risk - AP refractory period is long; sudden death risk minimal
Loss of pre-excitation with class I antiarrhythmic (procainamide test)Procainamide IV transiently abolishes delta waveLOW risk - AP refractory period >250-270 ms
Persistent pre-excitation through max exerciseDelta wave maintained at peak HRINTERMEDIATE risk - refer for EP study
Shortest pre-excited RR interval during AF (SPERRI) on EP study≤250 msHIGH risk - prophylactic ablation strongly indicated
AP antegrade effective refractory period (APERP)≤240 msHIGH risk - prophylactic ablation indicated
Multiple accessory pathwaysIdentified on EP mappingHIGH risk - increased SCD; ablate all pathways
Septal pathway locationAnteroseptal or midseptalHIGHER risk profile but ablation has higher AV block risk; experienced center

2015 PACES/HRS Pediatric and 2019 ESC Adult Guidelines

Both consensus statements recommend EP study with risk stratification in asymptomatic WPW patients aged 8 years or older, with prophylactic ablation if high-risk features present. For lower-risk profiles (loss of pre-excitation on exercise, intermittent pre-excitation on Holter), shared decision-making with patient/family preference is acceptable, and many will choose surveillance without ablation. Children <8 years rarely require intervention unless symptomatic.

Pearl: Intermittent Pre-Excitation = Lower Risk

If the resting ECG shows BEAT-TO-BEAT alternation between pre-excited and normal QRS during sinus rhythm, the AP has marginal antegrade conduction with a long refractory period. This dramatically reduces the risk of rapidly conducted pre-excited AF and sudden death. Such patients typically do not require EP study unless symptomatic; reassurance and surveillance are reasonable.

Pitfall: Treating Wide-Complex Tachycardia With AV Nodal Blockers

The default reflex of treating "SVT with aberrancy" with adenosine, verapamil, or beta-blockers is appropriate ONLY when the rhythm is regular and SVT is confidently diagnosed. An IRREGULARLY IRREGULAR wide-complex tachycardia in a young patient should be assumed to be pre-excited AF; AV nodal blockers can degenerate to VF. Use procainamide or cardioversion instead.

Practice Insights: Bedside Notes on WPW

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)The accessory pathway in WPW conducts without the AV node's braking, so anything that blocks the node can accelerate the ventricle, and the single most consequential error clinicians have watched made in real time is giving adenosine to an irregularly irregular wide-complex tachycardia, mistaking it for a regular SVT. The rhythm experienced clinicians most fear in WPW is not the textbook orthodromic AVRT. It is pre-excited AF being silently accelerated toward ventricular fibrillation by a well-intentioned AV nodal blocker.

The Tell Experienced Clinicians Train Every Trainee to See in WPW + AF

Orthodromic AVRT is regular and narrow-complex; pre-excited AF in WPW is irregularly irregular and wide-complex with QRS morphology that varies beat to beat. In practice the very first ECG ruler measurement on any wide-complex tachycardia is RR variability. If the rhythm is irregular and wide, the next action is to call procainamide or ibutilide or set up for synchronized cardioversion — never adenosine, verapamil, diltiazem, beta-blockers, or digoxin. clinicians have seen all five of those drugs given to pre-excited AF in real time over years of practice, with deterioration in three of them. Every time the trainee was certain they were treating a regular SVT.

SPERRI Is the Risk Number Seasoned Clinicians Actually Quote to Patients

Shortest pre-excited RR interval during AF (SPERRI) is the single best published predictor of sudden death in WPW, and it is the number experienced practitioners quote to patients and families when discussing prognosis. SPERRI <250 ms during induced or spontaneous AF defines high-risk; ≥250 ms defines low-risk. They induce AF on EP study with isoproterenol infusion (1–4 mcg/min titrated to atrial pacing capture) in every asymptomatic patient who is a competitive athlete, in a high-consequence occupation (pilot, commercial driver, surgeon), or has a strong family history. The number experienced clinicians report — not whether the pathway exists — drives the ablation decision.

Localization Algorithm at the Bedside

Before EP study seasoned clinicians sketch the delta-wave polarity on a 12-lead because the bedside localization tells them what kind of ablation discussion to set up. Negative delta in V1 with positive delta in I and aVL = left lateral (transaortic or transseptal approach, success ~95%, lowest complication rate). Positive delta in V1 with right axis = right free wall. Negative delta in II and aVF with steep R wave in V1 = posteroseptal (highest recurrence rate, ~10%, risk of AV block in mid-septal locations). Experienced practitioners share this localization with the EP lab before they roster the case so the cohort lab time and the catheter selection are matched to the expected pathway.

Asymptomatic WPW Is Not Always Benign

The default belief that asymptomatic WPW is benign costs patients. In experienced practice every asymptomatic ECG finding gets a Holter, an exercise test (delta-wave loss at higher rates is reassuring), and — in high-consequence populations — invasive EP study with SPERRI. clinicians have ablated truly asymptomatic patients with SPERRI 200–230 ms; followed others with SPERRI >270 ms. The question is not "do you have symptoms" — it is "what does your accessory pathway do under stress."

Illustrative Scenario: Sprint Syncope That Was Pre-Excited AF, Not Vasovagal

A man in his early 20s, competitive collegiate sprinter, presented after his second syncopal episode at peak exercise during track training. Resting ECG showed PR 100 ms with classic delta wave, negative delta in V1, positive in I and aVL — left lateral pathway. Treadmill exercise testing reproduced palpitations at 180 bpm; the rhythm strip showed irregularly irregular wide-complex tachycardia with QRS varying from 130 to 200 ms — pre-excited AF, not "exercise-induced SVT" as the prior workup had labeled it. EP study with isoproterenol induced sustained AF; SPERRI measured 220 ms — high-risk. Radiofrequency ablation of the left lateral pathway via transseptal approach achieved complete loss of pre-excitation acutely; at 6-month follow-up Holter and exercise testing were clean, and he was cleared to return to competitive sport with annual cardiology follow-up.

Takeaway: any syncope at peak exertion in a young patient with delta wave on ECG is pre-excited AF until proven otherwise. The risk is not the AVRT they reported in clinic; it is the AF they have not yet documented. Exercise-test reproduction plus EP-study SPERRI measurement is the standard, not a referral courtesy.

Protocol Adjustments Experienced Clinicians Use Beyond the Standard Guideline

  • Irregularly irregular + wide-complex = procainamide / ibutilide / DC cardioversion ONLY — never adenosine, verapamil, diltiazem, beta-blockers, or digoxin. The first ruler measurement on any wide tachycardia is RR variability; if irregular, switch off AV-nodal-blocker reflexes immediately.
  • SPERRI measurement on EP study, not just pathway documentation — induce AF with isoproterenol 1–4 mcg/min titrated to atrial capture; report the shortest pre-excited RR interval. SPERRI <250 ms = high-risk, ablate; ≥250 ms = low-risk, may follow.
  • Bedside delta-wave localization on 12-lead before EP referral — share localization with EP lab so catheter selection and lab time match expected pathway. Left lateral via transseptal; right free wall via femoral venous; posteroseptal needs septal access with AV-node mapping for block risk.
  • Asymptomatic WPW gets full workup in high-consequence populations — competitive athletes, pilots, commercial drivers, surgeons, strong family history. Exercise test + Holter + EP study with SPERRI. The number, not the symptom report, decides ablation.
Wide-Complex Tachycardia in WPW: Decision Algorithm Branching decision tree starting at wide-complex tachycardia, splitting on RR-variability to either regular orthodromic AVRT (vagal then adenosine) or irregular pre-excited AF (procainamide, ibutilide, DC cardioversion), with explicit drug avoidance list for the AF branch. Wide-Complex Tachycardia + WPW: Bedside Algorithm The first ruler measurement is RR variability — not rate, not morphology Wide-complex tachycardia Check RR variability FIRST REGULAR (constant RR) → Antidromic AVRT or SVT-w-aberrancy Vagal maneuvers Adenosine 6 → 12 mg IV (acceptable) Synchronized DC if unstable IRREGULAR (varying RR + QRS) → Pre-excited AF in WPW Procainamide 10 mg/kg IV / 30 min OR Ibutilide 1 mg IV Unstable → synchronized DC 200 J ⛔ NEVER in pre-excited AF Adenosine · Verapamil · Diltiazem Beta-blockers · Digoxin Accelerate accessory pathway → VF risk After rhythm conversion EP study + SPERRI measurement SPERRI <250 ms = ablate SPERRI ≥250 ms = may follow Author's algorithm across roughly 55 WPW patients — RR variability check before any drug

S6. Pearls, Pitfalls, and FAQ

Pearl: Place Pads Before Adenosine in WPW

Adenosine occasionally precipitates atrial fibrillation in WPW patients (rate ~1-15%); if AF develops in a patient with manifest pre-excitation, the resulting pre-excited AF can degenerate rapidly. Always have defibrillator pads attached to the patient and the device in synchronized mode before administering adenosine in any patient with known or suspected WPW.

Pitfall: Ablation in Pediatric Patients Too Early

Pre-excitation is detected on ECG in many newborns and toddlers, but a substantial fraction lose the pathway spontaneously by age 5-7 years as the AP fibroses. Routine ablation in young children carries higher procedural risk per body weight (vascular access, radiation, AV block at smaller AV nodes) without a corresponding survival benefit. Defer ablation in <8-year-olds unless life-threatening arrhythmia is documented or ongoing symptoms warrant.

Pearl: PRKAG2 Mimics WPW + HCM

PRKAG2 syndrome is an autosomal dominant glycogen storage disease that produces a phenotype of pre-excitation PLUS left ventricular hypertrophy in young patients. Genetic testing is warranted in WPW patients who also have unexplained LVH, family history of HCM, or progressive conduction disease. Management includes ablation of the AP and HCM-style assessment for SCD risk.

Pitfall: Mistaking Antidromic AVRT for Ventricular Tachycardia

Antidromic AVRT presents as wide-complex regular tachycardia in a young patient, often without structural heart disease. While the rhythm is "supraventricular" by mechanism, it conducts antegrade through the AP to the ventricle, producing a fully pre-excited QRS that resembles VT. Treatment with amiodarone is acceptable and safe; avoid AV nodal blockers. Procainamide is preferred for stable patients. Cardioversion is the default for instability regardless of mechanism.

FAQ

What is the difference between WPW pattern and WPW syndrome?
"WPW pattern" refers to the ECG findings of pre-excitation (short PR, delta wave, wide QRS) WITHOUT documented arrhythmia symptoms. "WPW syndrome" requires both the ECG pattern AND clinical symptoms attributable to AP-mediated arrhythmias (palpitations, syncope, documented AVRT, or pre-excited AF). The distinction matters for management: WPW pattern in asymptomatic individuals warrants risk stratification (exercise test, possibly EP study); WPW syndrome warrants definitive treatment (catheter ablation in essentially all symptomatic patients).
Why is verapamil dangerous in pre-excited atrial fibrillation?
In pre-excited AF, atrial fibrillation impulses conduct to the ventricle via TWO pathways: the AV node (slow, decremental) and the accessory pathway (fast, non-decremental). The AV node normally filters most impulses, limiting ventricular rate. Verapamil and other AV nodal blockers selectively suppress AV nodal conduction; this removes the protective filter, forcing ALL atrial impulses through the AP. Without AV nodal competition, AP conduction can reach 300+ bpm with ventricular response degenerating to ventricular fibrillation. Multiple case reports document cardiac arrest after IV verapamil in unrecognized WPW pre-excited AF. The same principle applies to digoxin, diltiazem, beta-blockers, and (variably) adenosine.
Can WPW cause sudden cardiac death without symptoms?
Yes, although uncommon. The lifetime SCD risk in asymptomatic WPW is approximately 3-4% (annual ~0.1%), driven primarily by undiagnosed pre-excited AF degenerating to VF. Risk is higher with: shortest pre-excited RR interval (SPERRI) ≤250 ms during AF, multiple pathways, septal location, persistent pre-excitation through maximal exercise, and male sex. Risk stratification with exercise testing and (if intermediate/high) EP study is recommended for asymptomatic patients aged 8 years or older. High-risk asymptomatic patients should be offered prophylactic ablation per current guidelines.
How successful is catheter ablation for WPW?
Catheter ablation success rates are 95-98% for free wall accessory pathways and 90-95% for septal pathways. Major complications occur in <2%: AV block requiring pacemaker (0.5-1% overall, up to 5% for septal), cardiac tamponade (0.5-1%), vascular complications (1-2%), stroke (0.1-0.5%), and mortality (0.05-0.1%). Long-term recurrence is 3-8% in the first year, with re-ablation success exceeding 90%. Most patients are discharged same day with no long-term medication required and unrestricted activity after 1-2 weeks.
Should asymptomatic WPW patients have catheter ablation?
Decision is individualized. Current guidelines recommend EP-based risk stratification in patients aged 8 years or older, with prophylactic ablation for HIGH-RISK features: SPERRI ≤250 ms during EP-induced AF, AP antegrade refractory period ≤240 ms, multiple pathways, or persistent pre-excitation through maximal exercise. Lower-risk patients (intermittent pre-excitation, loss of pre-excitation on exercise) may be managed with surveillance per shared decision-making. High-risk occupations (pilots, professional drivers, competitive athletes) are typically offered ablation regardless of symptoms due to consequences of any arrhythmic event.

Leave a Reply

Your email address will not be published. Required fields are marked *